Targeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery
暂无分享,去创建一个
[1] F. Gonzalez,et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G‐protein bile acid receptor‐1 signaling to improve metabolism , 2018, Hepatology.
[2] J. Trotter,et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2018, The Lancet.
[3] S. Kliewer,et al. FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. , 2017, Cell metabolism.
[4] D. Freyssenet,et al. Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice , 2017, Nature Medicine.
[5] F. Gonzalez,et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism , 2017, The Journal of Biological Chemistry.
[6] Deepak L. Bhatt,et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5‐Year Outcomes , 2017, The New England journal of medicine.
[7] S. Ikramuddin,et al. Bile Acids Increase Independently From Hypocaloric Restriction After Bariatric Surgery , 2016, Annals of surgery.
[8] F. Bäckhed,et al. Microbiota-induced obesity requires farnesoid X receptor , 2016, Gut.
[9] William H. Bisson,et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction , 2015, Nature Communications.
[10] R. Ley,et al. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice , 2015, Gut.
[11] F. Mottaghy,et al. The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. , 2015, Cell metabolism.
[12] N. Abumrad,et al. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery , 2015, Nature Communications.
[13] G. Shulman,et al. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis , 2015, Nature Communications.
[14] D. Rajpal,et al. Effect of Roux-en-Y Gastric Bypass Surgery on Bile Acid Metabolism in Normal and Obese Diabetic Rats , 2015, PloS one.
[15] B. Neuschwander‐Tetri,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.
[16] J. Holst,et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. , 2015, The Journal of clinical endocrinology and metabolism.
[17] D. Huson,et al. Effects of Surgical and Dietary Weight Loss Therapy for Obesity on Gut Microbiota Composition and Nutrient Absorption , 2015, BioMed research international.
[18] R. Haeusler,et al. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes , 2015, International Journal of Obesity.
[19] D. Brenner,et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance , 2015, Nature Medicine.
[20] I. Albert,et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. , 2015, The Journal of clinical investigation.
[21] M. Bueter,et al. The physiology of altered eating behaviour after Roux‐en‐Y gastric bypass , 2014, Experimental physiology.
[22] T. Arora,et al. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. , 2014, Cancer research.
[23] V. Tremaroli,et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy , 2014, Nature.
[24] R. Bergman,et al. FGF19 action in the brain induces insulin-independent glucose lowering. , 2013, The Journal of clinical investigation.
[25] B. Aronow,et al. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner , 2013, Obesity.
[26] M. Horowitz,et al. Effects of rectal administration of taurocholic acid on glucagon‐like peptide‐1 and peptide YY secretion in healthy humans , 2013, Diabetes, obesity & metabolism.
[27] S. Woods,et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. , 2013, Endocrinology.
[28] W. D. de Vos,et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women , 2012, Gut.
[29] N. Nagelkerke,et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers , 2012, Diabetologia.
[30] J. H. Bekker,et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. , 2012, Endocrinology.
[31] F. Gonzalez,et al. Bile Acids Acutely Stimulate Insulin Secretion of Mouse β-Cells via Farnesoid X Receptor Activation and KATP Channel Inhibition , 2012, Diabetes.
[32] F. Bäckhed,et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.
[33] K. Yoshinari,et al. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. , 2011, Biological & pharmaceutical bulletin.
[34] M. Orešič,et al. Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.
[35] S. Kliewer,et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. , 2011, Cell metabolism.
[36] S. Kliewer,et al. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis , 2011, Science.
[37] A. Peterson,et al. FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways , 2011, PloS one.
[38] L. Adorini,et al. Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist , 2010, Molecular Pharmacology.
[39] S. Woods,et al. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. , 2010, American journal of physiology. Gastrointestinal and liver physiology.
[40] B. Lemon,et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19) , 2010, Proceedings of the National Academy of Sciences.
[41] H. Itoh,et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. , 2009, Metabolism: clinical and experimental.
[42] J. Holst,et al. Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism , 2009, Obesity.
[43] B. Lemon,et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice , 2009, Proceedings of the National Academy of Sciences.
[44] W. Mckeehan,et al. FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver , 2007, Diabetes.
[45] Folkert Kuipers,et al. The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* , 2006, Journal of Biological Chemistry.
[46] Timothy M Willson,et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[47] R. Soriano,et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. , 2004, Endocrinology.
[48] D. French,et al. Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .
[49] Masahiro Tohkin,et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.
[50] G. Bray,et al. Suppression of appetite by bile acids. , 1968, Lancet.
[51] R. Haeusler,et al. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes , 2015, International Journal of Obesity.
[52] S. Woods,et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. , 2013, Endocrinology.